Report Summary
Biologics and Biosimilars-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Biologics and Biosimilars industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Biologics and Biosimilars 2013-2017, and development forecast 2018-2023
Main market players of Biologics and Biosimilars in Europe, with company and product introduction, position in the Biologics and Biosimilars market
Market status and development trend of Biologics and Biosimilars by types and applications
Cost and profit status of Biologics and Biosimilars, and marketing status
Market growth drivers and challenges
The report segments the Europe Biologics and Biosimilars market as:
Europe Biologics and Biosimilars Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Biologics and Biosimilars Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Antibody
Hormone
Growth Factors
Other
Europe Biologics and Biosimilars Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
Europe Biologics and Biosimilars Market: Players Segment Analysis (Company and Product introduction, Biologics and Biosimilars Sales Volume, Revenue, Price and Gross Margin):
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Interested in this report?
Get your sample now!
Table of Contents
Chapter 1 Overview of Biologics and Biosimilars
1.1 Definition of Biologics and Biosimilars in This Report
1.2 Commercial Types of Biologics and Biosimilars
1.2.1 Antibody
1.2.2 Hormone
1.2.3 Growth Factors
1.2.4 Other
1.3 Downstream Application of Biologics and Biosimilars
1.3.1 Tumor
1.3.2 Diabetes
1.3.3 Cardiovascular
1.3.4 Hemophilia
1.3.5 Other
1.4 Development History of Biologics and Biosimilars
1.5 Market Status and Trend of Biologics and Biosimilars 2013-2023
1.5.1 Europe Biologics and Biosimilars Market Status and Trend 2013-2023
1.5.2 Regional Biologics and Biosimilars Market Status and Trend 2013-2023
Chapter 2 Europe Market Status and Forecast by Regions
2.1 Market Status of Biologics and Biosimilars in Europe 2013-2017
2.2 Consumption Market of Biologics and Biosimilars in Europe by Regions
2.2.1 Consumption Volume of Biologics and Biosimilars in Europe by Regions
2.2.2 Revenue of Biologics and Biosimilars in Europe by Regions
2.3 Market Analysis of Biologics and Biosimilars in Europe by Regions
2.3.1 Market Analysis of Biologics and Biosimilars in Germany 2013-2017
2.3.2 Market Analysis of Biologics and Biosimilars in United Kingdom 2013-2017
2.3.3 Market Analysis of Biologics and Biosimilars in France 2013-2017
2.3.4 Market Analysis of Biologics and Biosimilars in Italy 2013-2017
2.3.5 Market Analysis of Biologics and Biosimilars in Spain 2013-2017
2.3.6 Market Analysis of Biologics and Biosimilars in Benelux 2013-2017
2.3.7 Market Analysis of Biologics and Biosimilars in Russia 2013-2017
2.4 Market Development Forecast of Biologics and Biosimilars in Europe 2018-2023
2.4.1 Market Development Forecast of Biologics and Biosimilars in Europe 2018-2023
2.4.2 Market Development Forecast of Biologics and Biosimilars by Regions 2018-2023
Chapter 3 Europe Market Status and Forecast by Types
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Biologics and Biosimilars in Europe by Types
3.1.2 Revenue of Biologics and Biosimilars in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Biologics and Biosimilars in Europe by Types
Chapter 4 Europe Market Status and Forecast by Downstream Industry
4.1 Demand Volume of Biologics and Biosimilars in Europe by Downstream Industry
4.2 Demand Volume of Biologics and Biosimilars by Downstream Industry in Major Countries
4.2.1 Demand Volume of Biologics and Biosimilars by Downstream Industry in Germany
4.2.2 Demand Volume of Biologics and Biosimilars by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Biologics and Biosimilars by Downstream Industry in France
4.2.4 Demand Volume of Biologics and Biosimilars by Downstream Industry in Italy
4.2.5 Demand Volume of Biologics and Biosimilars by Downstream Industry in Spain
4.2.6 Demand Volume of Biologics and Biosimilars by Downstream Industry in Benelux
4.2.7 Demand Volume of Biologics and Biosimilars by Downstream Industry in Russia
4.3 Market Forecast of Biologics and Biosimilars in Europe by Downstream Industry
Chapter 5 Market Driving Factor Analysis of Biologics and Biosimilars
5.1 Europe Economy Situation and Trend Overview
5.2 Biologics and Biosimilars Downstream Industry Situation and Trend Overview
Chapter 6 Biologics and Biosimilars Market Competition Status by Major Players in Europe
6.1 Sales Volume of Biologics and Biosimilars in Europe by Major Players
6.2 Revenue of Biologics and Biosimilars in Europe by Major Players
6.3 Basic Information of Biologics and Biosimilars by Major Players
6.3.1 Headquarters Location and Established Time of Biologics and Biosimilars Major Players
6.3.2 Employees and Revenue Level of Biologics and Biosimilars Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
Chapter 7 Biologics and Biosimilars Major Manufacturers Introduction and Market Data
7.1 Roche
7.1.1 Company profile
7.1.2 Representative Biologics and Biosimilars Product
7.1.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Roche
7.2 Amgen
7.2.1 Company profile
7.2.2 Representative Biologics and Biosimilars Product
7.2.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Amgen
7.3 AbbVie
7.3.1 Company profile
7.3.2 Representative Biologics and Biosimilars Product
7.3.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie
7.4 Sanofi-Aventis
7.4.1 Company profile
7.4.2 Representative Biologics and Biosimilars Product
7.4.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
7.5 Johnson & Johnson
7.5.1 Company profile
7.5.2 Representative Biologics and Biosimilars Product
7.5.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.6 Pfizer
7.6.1 Company profile
7.6.2 Representative Biologics and Biosimilars Product
7.6.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer
7.7 Novo Nordisk
7.7.1 Company profile
7.7.2 Representative Biologics and Biosimilars Product
7.7.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.8 Eli Lilly
7.8.1 Company profile
7.8.2 Representative Biologics and Biosimilars Product
7.8.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly
7.9 Novartis
7.9.1 Company profile
7.9.2 Representative Biologics and Biosimilars Product
7.9.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novartis
7.10 Merck
7.10.1 Company profile
7.10.2 Representative Biologics and Biosimilars Product
7.10.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Merck
7.11 3sbio
7.11.1 Company profile
7.11.2 Representative Biologics and Biosimilars Product
7.11.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio
7.12 Changchun High Tech
7.12.1 Company profile
7.12.2 Representative Biologics and Biosimilars Product
7.12.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Changchun High Tech
7.13 CP Guojian
7.13.1 Company profile
7.13.2 Representative Biologics and Biosimilars Product
7.13.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of CP Guojian
7.14 Biotech
7.14.1 Company profile
7.14.2 Representative Biologics and Biosimilars Product
7.14.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Biotech
7.15 Gelgen
7.15.1 Company profile
7.15.2 Representative Biologics and Biosimilars Product
7.15.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Gelgen
7.16 Innovent
7.17 Dong Bao
7.18 Ganlee
7.19 United Laboratories
Chapter 8 Upstream and Downstream Market Analysis of Biologics and Biosimilars
8.1 Industry Chain of Biologics and Biosimilars
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
Chapter 9 Cost and Gross Margin Analysis of Biologics and Biosimilars
9.1 Cost Structure Analysis of Biologics and Biosimilars
9.2 Raw Materials Cost Analysis of Biologics and Biosimilars
9.3 Labor Cost Analysis of Biologics and Biosimilars
9.4 Manufacturing Expenses Analysis of Biologics and Biosimilars
Chapter 10 Marketing Status Analysis of Biologics and Biosimilars
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
Chapter 11 Report Conclusion
Chapter 12 Research Methodology and Reference
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
List of Tables
Table Advantage and Disadvantage of Antibody
Table Advantage and Disadvantage of Hormone
Table Advantage and Disadvantage of Growth Factors
Table Advantage and Disadvantage of Other
Table Consumption Volume of Biologics and Biosimilars in Europe by Regions 2013-2017
Table Revenue of Biologics and Biosimilars in Europe by Regions 2013-2017
Table Consumption Volume of Biologics and Biosimilars in Europe by Regions 2018-2023
Table Revenue of Biologics and Biosimilars in Europe by Regions 2018-2023
Table Consumption Volume of Biologics and Biosimilars in Europe by Types 2013-2017
Table Revenue of Biologics and Biosimilars in Europe by Types 2013-2017
Table Consumption Volume of Biologics and Biosimilars by Types in Germany 2013-2017
Table Consumption Volume of Biologics and Biosimilars by Types in United Kingdom 2013-2017
Table Consumption Volume of Biologics and Biosimilars by Types in France 2013-2017
Table Consumption Volume of Biologics and Biosimilars by Types in Italy 2013-2017
Table Consumption Volume of Biologics and Biosimilars by Types in Spain 2013-2017
Table Consumption Volume of Biologics and Biosimilars by Types in Benelux 2013-2017
Table Consumption Volume of Biologics and Biosimilars by Types in Russia 2013-2017
Table Consumption Volume Forecast of Biologics and Biosimilars in Europe by Types 2018-2023
Table Revenue Forecast of Biologics and Biosimilars in Europe by Types 2018-2023
Table Demand Volume of Biologics and Biosimilars in Europe by Downstream Industry 2013-2017
Table Demand Volume of Biologics and Biosimilars by Downstream Industry in Germany 2013-2017
Table Demand Volume of Biologics and Biosimilars by Downstream Industry in United Kingdom 2013-2017
Table Demand Volume of Biologics and Biosimilars by Downstream Industry in France 2013-2017
Table Demand Volume of Biologics and Biosimilars by Downstream Industry in Italy 2013-2017
Table Demand Volume of Biologics and Biosimilars by Downstream Industry in Spain 2013-2017
Table Demand Volume of Biologics and Biosimilars by Downstream Industry in Benelux 2013-2017
Table Demand Volume of Biologics and Biosimilars by Downstream Industry in Russia 2013-2017
Table Demand Volume Forecast of Biologics and Biosimilars in Europe by Downstream Industry 2018-2023
Table Sales Volume of Biologics and Biosimilars in Europe by Major Players 2013-2017
Table Revenue of Biologics and Biosimilars in Europe by Major Players 2013-2017
Table Headquarters Location and Established Time of Biologics and Biosimilars Major Players
Table Employees and Revenue Level of Biologics and Biosimilars Major Players
Table Representative Biologics and Biosimilars Product One of Roche
Table Representative Biologics and Biosimilars Product Two of Roche
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Roche 2013-2017
Table Representative Biologics and Biosimilars Product One of Amgen
Table Representative Biologics and Biosimilars Product Two of Amgen
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Amgen 2013-2017
Table Representative Biologics and Biosimilars Product One of AbbVie
Table Representative Biologics and Biosimilars Product Two of AbbVie
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie 2013-2017
Table Representative Biologics and Biosimilars Product One of Sanofi-Aventis
Table Representative Biologics and Biosimilars Product Two of Sanofi-Aventis
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis 2013-2017
Table Representative Biologics and Biosimilars Product One of Johnson & Johnson
Table Representative Biologics and Biosimilars Product Two of Johnson & Johnson
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson 2013-2017
Table Representative Biologics and Biosimilars Product One of Pfizer
Table Representative Biologics and Biosimilars Product Two of Pfizer
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer 2013-2017
Table Representative Biologics and Biosimilars Product One of Novo Nordisk
Table Representative Biologics and Biosimilars Product Two of Novo Nordisk
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk 2013-2017
Table Representative Biologics and Biosimilars Product One of Eli Lilly
Table Representative Biologics and Biosimilars Product Two of Eli Lilly
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly 2013-2017
Table Representative Biologics and Biosimilars Product One of Novartis
Table Representative Biologics and Biosimilars Product Two of Novartis
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novartis 2013-2017
Table Representative Biologics and Biosimilars Product One of Merck
Table Representative Biologics and Biosimilars Product Two of Merck
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Merck 2013-2017
Table Representative Biologics and Biosimilars Product One of 3sbio
Table Representative Biologics and Biosimilars Product Two of 3sbio
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio 2013-2017
Table Representative Biologics and Biosimilars Product One of Changchun High Tech
Table Representative Biologics and Biosimilars Product Two of Changchun High Tech
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Changchun High Tech 2013-2017
Table Representative Biologics and Biosimilars Product One of CP Guojian
Table Representative Biologics and Biosimilars Product Two of CP Guojian
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of CP Guojian 2013-2017
Table Representative Biologics and Biosimilars Product One of Biotech
Table Representative Biologics and Biosimilars Product Two of Biotech
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Biotech 2013-2017
Table Representative Biologics and Biosimilars Product One of Gelgen
Table Representative Biologics and Biosimilars Product Two of Gelgen
Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Gelgen 2013-2017
